PKU6: INTERNATIONAL PSYCHOMETRIC VALIDATION AND CROSS-CULTURAL EQUIVALENCE OF A URINARY INCONTINENCE SPECIFIC QOL SCALE (CONTILIFE®) IN SIX EUROPEAN COUNTRIES  by Arnould, B et al.
450 Abstracts
OBJECTIVE: A significant portion of the population en-
dures economic, physical, and emotional burdens from
overactive bladder (OAB). OAB, with and without incon-
tinence, causes strong, sudden, and unpredictable urges
to urinate. People with OAB may be at greater risk for
urinary tract infections (UTIs), falls and fractures, and in-
creased medical visits, but to date, the extent to which
consequent treatment costs are associated with OAB is
unknown.
METHODS: The National Overactive BLadder Evalua-
tion (NOBLE) Program included a US survey of 5204 En-
glish-speaking adults over 18 years to estimate the preva-
lence of OAB. All OAB cases and age- and gender-matched
controls were sent a follow-up questionnaire to assess the
occurrence of UTIs, falls, and medical visits in the past
year. A total of 397 (46%) patients and 522 (57%) con-
trols returned the questionnaires. The non-response rate of
patients and controls did not differ with age, gender, edu-
cational status, diabetes, congestive heart failure, or self-
rated health status. UTIs and physician visits were analy-
sed using multivariate regression models, controlling for
age, gender, race, education, marital status, births, self-
reported health status, and presence of diabetes and con-
gestive heart failure.
RESULTS: People with OAB averaged 20% more physi-
cian visits (P  .001), had 57% more UTIs in the last
year (P  .001), and had over twice the odds of being in-
jured in a fall than people without OAB (OR  2.26;
95% CI 1.46, 3.51; P  .001). Sensitivity analyses (re-
moving 5% of the outliers as identified with Cook’s dis-
tance) indicated that the effects were robust. Cost esti-
mates associated with OAB in the year 2000 were
approximately $1.37 billion and $273 million US dollars
for UTIs and falls/broken bones, respectively.
CONCLUSIONS: OAB increases the risk for UTIs and
fall injuries and results in more physician visits. OAB-
related costs were over $1.6 billion US dollars in 2000.
Effective treatment would likely reduce these costs.
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OBJECTIVE: Despite the significant impact of urinary in-
continence (UI) on patient’s Quality of Life (QoL), there is a
lack of internationally validated instruments to assess QoL.
METHODS: CONTILIFE® is a specific UI 28-item QoL
scale, measuring six dimensions: Daily Activities (DA);
Effort Activities (EA); Self Image (SI); Emotional Impact
(EI); Sexuality (SX); Well Being (WB). QoL was assessed
at inclusion and after a four-week treatment period in
505 UI women from Belgium, Denmark, France, Germany,
the Netherlands and the UK (mean age: 51years 
 11; mean
number of urinary leakages over the past 7 days: 16 
 14).
The validity, reliability and sensitivity to change over time
were assessed according to standard guidelines. In addition,
Rasch modeling and Multiple Factor Analysis (MFA) were
used to assess the cross-cultural equivalence and the stability
over time of the CONTILIFE.
RESULTS: According to the number of urinary leakages
(NUL) the clinical validity was very good. All scores were
highly correlated (p  .007) with the NUL. The QoL
scores were responsive to NUL improvement (effect sizes 
0.4), except for the SX and WB dimensions. The con-
struct validity was good (Chronbach alpha  0.7), with
scaling success over 90% in all dimensions except DA
(convergent validity 86%). The severity of the items was
consistent across countries according to Rasch, but MFA
showed a limited equivalence of the underlying construct
across countries. Nevertheless, the stability of the scale’s
structure over the four-week period was excellent.
CONCLUSION: CONTILIFE demonstrated its overall
validity, reliability and sensitivity to change over time in
this international sample. These good properties allow re-
searchers to include this QoL measure as an endpoint in
international clinical trials dealing with female UI.
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OBJECTIVE: To demonstrate that the progressive eleva-
tion of the threshold for definition of treatment response
elucidates the greater likelihood of patients with schizo-
phrenia responding to the novel antipsychotic olanzapine
(OLZ) as compared to haloperidol (HAL).
METHODS: Data was analyzed post-hoc from the acute
phase of a large, prospective, randomized (OLZ versus
HAL, mean modal dose  13.2 versus 11.8 mg/day, re-
spectively), double-blind trial, conducted in 17 countries
with 1996 patients who met the DSM-III-R criteria for
schizophrenia, schizophreniform disorder, or schizoaffec-
tive disorder. The cumulative proportion of patients
achieving a priori defined response criteria at each of
three thresholds was determined. Thresholds for clinical
improvement were 20% or greater, 40% or greater, and
65% or greater reduction in endpoint to baseline Brief
Psychiatric Rating Scale (BPRS) total scores. At each
week, chi-square tests were used to compare the propor-
tion of OLZ-treated patients versus the proportion of
